N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

Sponsor: Regeneron Pharmaceuticals • ClinicalTrials.gov ID: NCT07318597

Registry updated: 2026-09-25
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines. The study is looking at several other research questions, including: * What side effects may happen from taking REGN13335 * How much REGN13335 is in the blood at different times * Whether the body makes antibodies against REGN13335 (which could make REGN13335 less effective or could lead to side effects)

Interventions

  • REGN13335 (Drug)
    Administered per the protocol
  • Placebo (Drug)
    Administered per the protocol

Eligibility criteria

Key Inclusion Criteria: 1. Documented clinical diagnosis of PAH (Group 1 PH according to the 7th World Symposium on Pulmonary Hypertension (WSPH)) 2. WHO functional class II or III (slight to marked limitation of functional status due to PAH) 3. Receiving background Standard Of Care (SOC) therapy for PAH on a stable dose and regimen, as determined by the investigator, as described in the protocol 4. PVR ≥400 dynes∙sec/cm\^5 (5 Wood units) based on Right Heart Catheterization (RHC) during the screening period 5. Has 6MWD ≥150 and ≤550 meters repeated twice during screening as described in the protocol Key Exclusion Criteria: 1. Has Group 2 (PH associated with left heart disease), Group 3 (PH associated with lung diseases and/or hypoxia), Group 4 (PH associated with pulmonary artery obstructions), or Group 5 (PH with unclear and/or multifactorial mechanisms) PH according to the 7th WSPH 2. Pulmonary Arterial Wedge Pressure (PAWP) \>15 mm Hg by RHC during the screening period 3. History of left-sided heart disease and/or clinically significant cardiac disease, as described in the protocol 4. Obstructive lung disease defined as Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity \<0.7 and FEV1 \<70% of the predicted value as described in the protocol 5. Evidence of interstitial lung disease as defined in the protocol 6. Evidence of chronic thromboembolic pulmonary disease or acute pulmonary embolism as described in the protocol 7. Participants requiring anticoagulation and/or antiplatelet therapy for an underlying medical condition as described in the protocol 8. Has any history of intracranial bleeding or any history of elevated intracranial pressure 9. Has any history of bleeding meeting criteria as described in the protocol Note: Other protocol-defined Inclusion/ Exclusion criteria apply

Conditions

Pulmonary Arterial Hypertension (PAH)

Locations

  • University of Colorado Denver — Aurora, Colorado, United States
  • Tufts Medical Center — Boston, Massachusetts, United States
  • University of Nebraska Medical Center - 2365 — Omaha, Nebraska, United States
  • University of Cincinnati — Cincinnati, Ohio, United States
  • The Prince Charles Hospital — Brisbane, Queensland, Australia
  • Mater Misericordiae Ltd — South Brisbane, Queensland, Australia
  • Royal Hobart Hospital — Hobart, Tasmania, Australia
  • UZ Leuven — Leuven, Vlaams-Brabant, Belgium
  • H.U.B. Erasme Hospital — Brussels, Belgium
  • Hopital Bicetre — Le Kremlin-Bicêtre, France
  • Nouvel hopital civil — Strasbourg, France
  • Universitatsklinikum Halle — Halle, Saxony-Anhalt, Germany
  • Clinic of University Greifswald — Greifswald, Germany
  • Universitatsmedizin Mainz — Mainz, Germany
  • P. Stradins Clinical University hospital — Riga, Latvia
  • University Clinical Hospital in Poznan - Early Phase Unit — Poznan, Greater Poland Voivodeship, Poland
  • University Hospital in Bialystok — Bialystok, Podlaskie Voivodeship, Poland
  • Oddzial Kardiologiczny — Lodz, Łódź Voivodeship, Poland
  • Gachon University Gil Medical Center — Namdong-gu, Incheon, South Korea
  • Asan Medical Center — Seoul, Songpa-gu, South Korea
  • Seoul National University Hospital — Seoul, South Korea
  • Severance Hospital — Seoul, South Korea
  • Samsung Medical Center — Seoul, South Korea
  • Hospital Vall d'Hebron — Barcelona, Catalonia, Spain
  • Hospital Universitario Costa del Sol — Marbella, Malaga, Spain
  • Hospital Clinic, Barcelona — Barcelona, Spain
  • University hospital 12 de octubre — Madrid, Spain
  • University Hospital Salamanca — Salamanca, Spain
  • Hospital Universitario De Toledo — Toledo, Spain
  • Royal United Hospitals Bath NHS Foundation Trust — Bath, United Kingdom
  • Royal Free Hospital — London, United Kingdom
  • Imperial College Healthcare NHS Trust, Hammersmith Hospital — London, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record